5.79
5.79 (0%)
As of Feb 14, 2025
ARDELYX, INC. [ARDX]
Source:
Company Overview
Ardelyx, Inc is a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. We developed a unique and innovative platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines.
| Country | United States |
| Headquarters | fremont, california |
| Phone Number | 510-745-7047 |
| Industry | manufacturing |
| CEO | Michael Raab |
| Website | www.ardelyx.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $333.6 |
| Operating Profit | $-28 |
| Net Income | $-39.1 |
| Net Cash | $43.5 |
Profit Ratios
| Gross Margin | $283.1 |
| Operating Margin | -8.4 |
| Profit as % of Revenues | -723.3% |
| Profit as % of Assets | -10.7% |
| Profit as % of Stockholder Equity | -22.6% |
Management Effectiveness
| Return on Equity | -22.6% |
| Return on Assets | -9% |
| Turnover Ratio | 91% |
| EBITA | $-28 |
Balance Sheet and Cash Flow Measures
| Total Assets | $435.8 |
| Total Liabilities | $262.5 |
| Operating Cash Flow | $-44.8 |
| Investing Cash Flow | $-18.3 |
| Financing Cash Flow | $106.6 |
